ROIV - Roivant Sciences Ltd.
About Roivant Sciences Ltd. (https://roivant.com)
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Eric Venker | President & Chief Executive Officer of Immunovant | 1987 | $22,138,302 USD |
| Frank Torti | President & Vant Chair | 1979 | $13,961,770 USD |
| Matthew Gline | Chief Executive Officer & Director | 1984 | $3,096,190 USD |
| Richard Pulik | Chief Financial Officer | 1980 | $1,752,034 USD |
| Mayukh Sukhatme | President, Chief Investment Officer & Director | 1976 | $1,276,655 USD |
| Jennifer Humes | Chief Accounting Officer | 1981 | $324,640 USD |
| Alex Gasner | Executive Vice President of Roivant Health | – | – |
| Deya Corzo | Chief Medical Officer-In-Residence | 1967 | – |
| Huafeng Xu | Chief Technology Officer | – | – |
| Ian Rosenblum | Chief Information Officer | – | – |
| Josh Chen | General Counsel | – | – |
| Kelly Graff | Head of People | – | – |
| Sam Kaplan | General Counsel | – | – |